Focus on biological agents in rheumatoid arthritis: Newer treatments and therapeutic strategies;Le point sur les biothérapies dans la polyarthrite rhumatoïde: Principes actifs disponibles, stratégie thérapeutique

Therapie

Volumn 59, Issue 4, 2004, Pages 451-461

  Fanet Goguet, Marianne ^a   Martin, Sylvie ^a   Fernandez, Christine ^a,b   Fautrel, Bruno ^a   Bourgeois, Pierre ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Biological; Interleukin 1 inhibitor; Rheumatoid arthritis; TNF blocking agent

Indexed keywords

ADALIMUMAB; ALLOCHRYSINE; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G1; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; LENERCEPT; MACROGOL; METHOTREXATE; MONOCLONAL ANTIBODY; PENICILLAMINE; PLACEBO; PROTEIN P75; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TIOPRONIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

ALOPECIA; BLOOD TOXICITY; BONE INJURY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FRANCE; HEART FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MOUTH ULCER; NAUSEA; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; TUBERCULOSIS;

EID: 8444229715     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2004077     Document Type: Conference Paper

References (51)

1. Agence Française de Sécurité Sanitaire des Produits de Santé (Afssaps). Enbrel®. Avis de la Commission de transparence du 2 octobre 2002. Available from URL: http://www.agmed.sante.gouv.fr [Accessed 2003 Apr 1]
2. European Agency for the Evaluation of Medicinal Products (EMEA): Committee for Proprietary Medicinal Products. European Public Assessment Report (EPAR). Enbrel®. Rev. 2, 2002 Apr 15: 47 pp
3. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7
4. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478-86
5. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9
6. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93
7. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50
8. US Food and Drug Administration (US FDA). Update on the TNF blocking agents: briefing document. Arthritis Advisory Committee. 2003 Mar 4 [online]. Available from URL: http://www.fda.gov [Accessed 2003 Apr 1]
9. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 2565-70
10. Deswal A, Bozkurt B, Seta Y. Safety and efficacy of a soluble p75 TNF receptor (Enbrel, Etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224-6
11. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumour necrosis factor therapy with etanercept (Enbrel®) in patients with advanced heart failure. Circulation 2001; 103: 1044-7
12. Kwon HJ, Coté TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-11
13. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9
14. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis Rheum 2002; 46: 3151-8
15. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-80
16. Cairns AP, Duncan MK, Hinder AE, et al. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002; 61: 1031-2
17. Moreland LW, Heck Jr LW, Koopman WJ. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997; 40: 397-409
18. Rankin EC, Choy EH, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34; 334-42
19. Choy EHS, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002; 41: 1133-7
20. Schering-Plough. Monographie Remicade®. Mars 2001
21. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90
22. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9
23. Lipsky PE, St Clair W, Furst D, et al. 54-week clinical and radiographical results from the ATTRACT trial: a phase III study of infliximab (Remicade®) in patients with active RA despite methotrexate [abstract]. Arthritis Rheum 1999; 42: S401
24. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45
25. Wagner CL, St Clair EW, Han C, et al. Effects of antibodies to infliximab on ACR response in patients with rheumatoid arthritis in the ATTRACT study [abstract]. Arthritis Rheum 2002; 46: S132
26. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8
27. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-9
28. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9
29. Centocor. Important drug warning: Remicade®. 2001 Oct 18 [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2001/remicade_deardoc.pdf [Accessed 2004 Sep 6]
30. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45
31. Keystone E, Kavanaugh AF, Sharp J, et al. Adalimumab (D2E7), a fully human anti-TNFα monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [abstract]. Arthritis Rheum 2002; 46: S205
32. Furst DE, Schiff M, Fleischmann R, et al. Safety and efficacy of adalimumab (D2E7), a fully human anti-TNFα monoclonal antibody, given in combination with standard antirheumatic therapy: safety trial of adalimumab in rheumatoid arthritis (STAR) [abstract]. Arthritis Rheum 2002; 46: S572
33. Salmon D. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002; 69: 170-2
34. Dayer JM, Feige U, Edwards III CK, et al. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol 2001; 13: 170-6
35. Pavelka K, Kuba V, Rasmussen JM, et al. Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1 beta converting enzyme (ICE) inhibitor, in a 285 patient ph.II trial in rheumatoid arthritis (RA) [abstract no. LB02]. ACR: 2002 Oct; New Orleans
36. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204
37. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001-9
38. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24
39. Nuki G, Bresnihan B, Bear MB, et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 2838-46
40. Fleischmann R, Tesser J, Sun G. Safety of anakinra (interleukin-1 receptor antagonist) in patients receiving standard treatments for rheumatoid arthritis: a large phase III study [abstract]. Arthritis Rheum 2002; 46: S574
41. Choy EHS, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46: 3143-50
42. Nishimoto N, Yoshizaki K, Miyasaka N, et al. A multi-center, randomized, double-blind, placebo-controlled trial of humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody (MRA) in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2002; 46: S559
43. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2002; 46:S197
44. Moreland LW, Alten R, Van den Bosch F, et al. Costimulating blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blinded, placebo-controlled clinical trial evaluating CTLA4-Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46: 1470-9
45. Kremer J, Westhovens R, Leon M, et al. A phase 2B, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of CTLA4-Ig administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate [abstract]. Arthritis Rheum 2002; 46: S203
46. Emery P, Williams GR, Li T, et al. Treatment of patients with active rheumatoid arthritis using methotrexate with CTLA4-Ig improves health-related quality of life [abstract]. Ann Rheum Dis 2002; 61: 337
47. The National Institute for Clinical Excellence (NICE). The clinical effectiveness and cost effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. 2001 Sep 3: 138 [online]. Available from URL: http://www.nice.org.uk [Accessed 2004 Sep 11]
48. Wallis WJ, Burge DJ, Holman J, et al. Infection reports with etanercept (Enbrel®) therapy [abstract]. Arthritis Rheum 2001; 44: S78
49. Cohen J. The secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis [abstract no. THU 0192]. EULAR: 2003 Jun; Lisbon
50. Buch MH. Do patients with rheumatoid arthritis with high disease activity on infliximab demonstrate improvement on etanercept? [abstract no. THU 0237]. EULAR: 2003 Jun; Lisbon
51. Haraoui PB, Keystone EC, Thorne JC, et al. The Canadian biologic observational switchover survey (BOSS): switching from infliximab to etanercept leads to successful treatment of rheumatoid arthritis [abstract no. THU 0226]. EULAR: 2003 Jun; Lisbon